These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 24993156)

  • 1. Factor XII: a drug target for safe interference with thrombosis and inflammation.
    Kenne E; Renné T
    Drug Discov Today; 2014 Sep; 19(9):1459-64. PubMed ID: 24993156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factor XII: a novel target for safe prevention of thrombosis and inflammation.
    Kenne E; Nickel KF; Long AT; Fuchs TA; Stavrou EX; Stahl FR; Renné T
    J Intern Med; 2015 Dec; 278(6):571-85. PubMed ID: 26373901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk.
    Larsson M; Rayzman V; Nolte MW; Nickel KF; Björkqvist J; Jämsä A; Hardy MP; Fries M; Schmidbauer S; Hedenqvist P; Broomé M; Pragst I; Dickneite G; Wilson MJ; Nash AD; Panousis C; Renné T
    Sci Transl Med; 2014 Feb; 6(222):222ra17. PubMed ID: 24500405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor XII as a Therapeutic Target in Thromboembolic and Inflammatory Diseases.
    Nickel KF; Long AT; Fuchs TA; Butler LM; Renné T
    Arterioscler Thromb Vasc Biol; 2017 Jan; 37(1):13-20. PubMed ID: 27834692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclic peptide FXII inhibitor provides safe anticoagulation in a thrombosis model and in artificial lungs.
    Wilbs J; Kong XD; Middendorp SJ; Prince R; Cooke A; Demarest CT; Abdelhafez MM; Roberts K; Umei N; Gonschorek P; Lamers C; Deyle K; Rieben R; Cook KE; Angelillo-Scherrer A; Heinis C
    Nat Commun; 2020 Aug; 11(1):3890. PubMed ID: 32753636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factor XII(a) inhibitors: a review of the patent literature.
    Kalinin DV
    Expert Opin Ther Pat; 2021 Dec; 31(12):1155-1176. PubMed ID: 34142629
    [No Abstract]   [Full Text] [Related]  

  • 7. New agents for thromboprotection. A role for factor XII and XIIa inhibition.
    Labberton L; Kenne E; Renné T
    Hamostaseologie; 2015; 35(4):338-50. PubMed ID: 25609114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factor XII promotes the thromboinflammatory response in a rat model of venoarterial extracorporeal membrane oxygenation.
    Kharnaf M; Zafar F; Hogue S; Rosenfeldt L; Cantrell RL; Sharma BK; Pearson A; Sprague C; Leino D; Abplanalp WA; Zelek WM; McCrae KR; Shim YJ; Morales D; Tweddell J; Qualls JE; Palumbo JS
    J Thorac Cardiovasc Surg; 2024 Aug; 168(2):e37-e53. PubMed ID: 37683721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer.
    Woodruff RS; Xu Y; Layzer J; Wu W; Ogletree ML; Sullenger BA
    J Thromb Haemost; 2013 Jul; 11(7):1364-73. PubMed ID: 23692437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The factor XIIa blocking antibody 3F7: a safe anticoagulant with anti-inflammatory activities.
    Worm M; Köhler EC; Panda R; Long A; Butler LM; Stavrou EX; Nickel KF; Fuchs TA; Renné T
    Ann Transl Med; 2015 Oct; 3(17):247. PubMed ID: 26605293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factor XII/XIIa inhibitors: Their discovery, development, and potential indications.
    Davoine C; Bouckaert C; Fillet M; Pochet L
    Eur J Med Chem; 2020 Dec; 208():112753. PubMed ID: 32883641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single-domain antibody targeting factor XII inhibits both thrombosis and inflammation.
    Xu P; Zhang Y; Guo J; Li H; Konrath S; Zhou P; Cai L; Rao H; Chen H; Lin J; Cui Z; Ji B; Wang J; Li N; Liu DP; Renné T; Wang M
    Nat Commun; 2024 Sep; 15(1):7898. PubMed ID: 39266545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis.
    Kleinschnitz C; Stoll G; Bendszus M; Schuh K; Pauer HU; Burfeind P; Renné C; Gailani D; Nieswandt B; Renné T
    J Exp Med; 2006 Mar; 203(3):513-8. PubMed ID: 16533887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
    Melo FR; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FXIIa inhibitor rHA-Infestin-4: Safe thromboprotection in experimental venous, arterial and foreign surface-induced thrombosis.
    May F; Krupka J; Fries M; Thielmann I; Pragst I; Weimer T; Panousis C; Nieswandt B; Stoll G; Dickneite G; Schulte S; Nolte MW
    Br J Haematol; 2016 Jun; 173(5):769-78. PubMed ID: 27018425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor XIIa inhibition by Infestin-4: in vitro mode of action and in vivo antithrombotic benefit.
    Xu Y; Cai TQ; Castriota G; Zhou Y; Hoos L; Jochnowitz N; Loewrigkeit C; Cook JA; Wickham A; Metzger JM; Ogletree ML; Seiffert DA; Chen Z
    Thromb Haemost; 2014 Apr; 111(4):694-704. PubMed ID: 24336918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticoagulation beyond direct thrombin and factor Xa inhibitors: indications for targeting the intrinsic pathway?
    van Montfoort ML; Meijers JC
    Thromb Haemost; 2013 Aug; 110(2):223-32. PubMed ID: 23739841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factor XII inhibition reduces thrombus formation in a primate thrombosis model.
    Matafonov A; Leung PY; Gailani AE; Grach SL; Puy C; Cheng Q; Sun MF; McCarty OJ; Tucker EI; Kataoka H; Renné T; Morrissey JH; Gruber A; Gailani D
    Blood; 2014 Mar; 123(11):1739-46. PubMed ID: 24408325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factor XI and factor XII as targets for new anticoagulants.
    Weitz JI
    Thromb Res; 2016 May; 141 Suppl 2():S40-5. PubMed ID: 27207423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A nanobody-based method for tracking factor XII activation in plasma.
    de Maat S; van Dooremalen S; de Groot PG; Maas C
    Thromb Haemost; 2013 Sep; 110(3):458-68. PubMed ID: 23349032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.